Overview

Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer

Status:
Recruiting

Trial end date:
2023-03-31

Target enrollment:

Participant gender:

Summary

This study aims to investigate the efficacy and safety of olanzapine combined with fosaprepitant, ondansetron and dexamethasone compared with placebo combined with fosaprepitant, ondansetron and dexamethasone in the prevention of nausea and vomiting in germ-cell tumors receiving 5-day cisplatin chemotherapy

Phase:

Phase 3

Details

Lead Sponsor:

Shi Yanxia

Treatments:

Olanzapine